About: Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.79 (-0.35%)
HIND NASDAQ Vyome Holdings, Inc.
Vyome Holdings, Inc. share price
Atividade de preço de HIND
Último preço
$ 1,790
Variação (24h)
-0,01 USD (0,35%)
Volume
623
Volume (média 4 sem.)
-
Abertura
$ 1,79
Variação do dia
$ 1,79 - $ 1,79
Fechamento anterior
$ 1,80
Último negócio
23 Oct, 2:12 pm GMT+0
Atrasado
23 Oct, 2:12 pm GMT+0
HIND price performance
Atrasado
23 Oct, 2:12 pm GMT+0
quote.marketSignals